PropThink’s Weekly Healthcare Wrap-Up
Most Popular - IMUC proved a successful trade in the short-term, climbing 34% since our report was published on the first of the month. In early trials, lead … Continue Reading
Read nowSearch Results for endo health
PropThink’s Weekly Healthcare Recap
Most Popular - A catalyst-rich 2013 and a solid financial position for BioMarin should push the stock higher. Since we published this story on Monday, shares of the drug … Continue Reading
Read nowA Look at the Week in Healthcare and Biotech
Most Popular - Abbot Labs recorded the first sale of Amitiza in Japan, resulting in a $15M milestone payment to Sucampo on Tuesday. Nevertheless, the thinly-traded equity reacted … Continue Reading
Read now‘Trouble Is Opportunity’; Endo Fallout is Worth A Look
Long Ideas - It’s not easy to do, but buying when there’s blood in the streets is a way many have scored big on Wall Street. Take our … Continue Reading
Read nowPropThink’s Weekly Healthcare Wrap-Up
Most Popular - Pharmacyclics warned in its 3Q earnings release that employees might sell market-moving amounts of shares on Wednesday as they exercised options. As we expected, shares … Continue Reading
Read nowWeekly Recap: PropThink’s Latest in Healthcare and Biotech
Most Popular - Gilead paid a lot of money – $11B to be exact – to acquire Pharmasset back in 2011. Was it worth it? Propthink dug in … Continue Reading
Read now
